# Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy

Study · id `cardio:ct-nct01175486` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01175486](<https://clinicaltrials.gov/study/NCT01175486>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01175486

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01175486. Randomized; no masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01175486, source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)
- Start date: 2010-07 (registry gives no type) (ClinicalTrials.gov record NCT01175486, source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)
- Primary completion: 2012-12 (anticipated) (ClinicalTrials.gov record NCT01175486, source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01175486, source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT01175486, source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01175486-2011-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
- Condition: Diabetes
- Intervention (Drug): Actos (Pioglitazone)
- Intervention (Drug): Acarbose
- Lead sponsor: Taipei Veterans General Hospital, Taiwan
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Taipei Veterans General Hospital, Taiwan (`cardio:org-taipei-veterans-general-hospital-taiwan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study (`cardio:pubmed-27812149`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1cb76793354a42c4645868aa291dfacbe20595fdc3bfef671e7e902d3318d99b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
